Figure 1.

Clinical trial schema. Bladder cancer patients are treated with 2 doses of anti-CTLA-4 antibody at 3 mg/kg at study weeks 0 and 3 prior to undergoing surgery at study week 7 and post-operative follow-up visits at study weeks 11-15 and 23-24. Blood is collected as: pre-therapy samples prior to administration of the first dose of antibody at study week 0; after dose #1 at study week 3 prior to administration of dose #2; after dose #2 at study week 7 prior to surgery; and at each post-op visit.